RhoVac attends the BIO-Europe Spring, Vienna, Austria.

RhoVac AB ("RhoVac") will participate in BIO-Europe Spring in Vienna, Austria in March 2019.

From 25 to 27 March 2019, RhoVac will attend the 13th Annual International Partnering Conference BIO-Europe Spring in Vienna, Austria. Approximately 1,500 different companies, academic institutions and other related organizations from around 55 countries attend the meeting.

To schedule a meeting with RhoVac, it is possible to register this via the BIO-Europe's online partnership platform at: www.partneringone.com. 

For more information, please contact:

Anders Ljungqvist – CEO, RhoVac AB

Phone: +45 4083 2365

E-mail: alj@rhovac.com

About RhoVac AB

RhoVac AB conducts research and development of immunotherapeutic drugs. The Company’s main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer.  RhoVac’s first drug candidate has completed pre-clinical and clinical phase I/II. RhoVac has its headquarters at Medicon Village in Lund, Sweden. Since 2007, research is conducted primarily at the University Hospital in Herlev, Denmark and at University of Tübingen by research teams of world-class in their field. RhoVac is listed on Spotlight Stock Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Learn more at www.rhovac.com.